<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
	<title>Pharmacology</title>
	<meta name='Generator' content='Zim 0.73.1'>
	<style type='text/css'>
		a          { text-decoration: none      }
		a:hover    { text-decoration: underline }
		a:active   { text-decoration: underline }
		strike     { color: grey                }
		u          { text-decoration: none;
					 background-color: yellow   }
		tt         { color: #2e3436;            }
		pre        { color: #2e3436;
					 margin-left: 20px          }
		h1         { text-decoration: underline;
					 color: #4e9a06; margin-bottom: 0 }
		h2         { color: #4e9a06; margin-bottom: 0 }
		h3         { color: #4e9a06; margin-bottom: 0 }
		h4         { color: #4e9a06; margin-bottom: 0 }
		h5         { color: #4e9a06; margin-bottom: 0 }
		p          { margin-top: 0              }
		span.zim-tag {
			color: #ce5c00;
		}
		div.zim-object {
			border-style:solid;
			border-width:1px;
		}
		.checked-box {list-style-image: url(data:image/png;base64,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)}
		.xchecked-box {list-style-image: url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABgAAAAYCAYAAADgdz34AAAAAXNSR0IArs4c6QAAAAZiS0dEAP8A/wD/oL2nkwAAAAlwSFlzAAANOgAADMQBiN+4gQAAAAd0SU1FB9gKGQ8bDYnDxEwAAAAZdEVYdENvbW1lbnQAQ3JlYXRlZCB3aXRoIEdJTVBXgQ4XAAAEK0lEQVRIx9WVS2hTWRjHf/eR3CY1nbxMH2YiZRQS6qO13YlMVxY3SnVcuNIBFezGpSADLoQqLu1sHJCqdCFSXFpw4YOCSH3BtFqttTNamabX3DS5bfO6uffMoglja3RGcDMHzuac7/z/53++//cd+L8P6VuCPQYZ8ADNgBd4J31DcDcQs+GnHByRocEDv0kfBSjAOlYCs11Q+gpwDegS8LMJ+3QIK0ATzEhV8Odnz5bzw8P4dJ25aJQ/WlvJ1df/K7hSLtOcTNI+Pk69rpMTgqIQhCDvh1/VSpw79+gRrRMTmLZNezLJJsPg+a5dmOEwQlFqg1sWG16/Jv7sGWXDwBACFQjC9HcwIMONKkGp4PGAJGEDS0IQmZlhnWnye3c3eiyGo6qr3WHbrJ+dJf7gAXI6zSIr72T7/fgzmT4FHnTBsgrQBfYvTU0km5vxz86iADnAm0rRPTWFt7cXZccOJJcLAGHb2K9ekT93jmwmwwdAAFpjI6Ntbfxw5879ag7l6o1sr5eHHR3IsRgeQK/M4sQE+YEB7JcvEY6zAj45SWFgAPPxYwzHoQxIkQjTPT0kIxE+Noj8sexFn4/xnh58iQTeSpHkHAdrbIzi0BCOrmNPTpK/eJHM3bt8sCyKQCiR4NWePWSiUZw1+ZLXJm4pFKLhzBlCsRh2RUXacVgeGaF47RrL58+zcP8+RrmMkCQinZ1EL1zAjERqmkH+tLYl1G3bCJw4QUjT0IA0MJfLMX/5MqmHD0nZNiUgtGULG/r7ccXjINWuWbnmqsuFu7sb/4EDNLlcBIEioNs2KUAFGmMxmk6dQm1tRZI+3xBqEkiShBQOox05Ql1nJ26gvuIUAWiKQnj/ftStW5Fk+YuF+NldsbBA4cYN9KdPmaso8Fc62ZJtk7l1C2t0FGdxESHE1xE4hkHh6lX0oSHSpRIewC/LrPf7CSgKNpCamkI/fZr8pUuIZBIcpyaBunahPp1mub+fDyMjGKUSChCsq6Nh717q9u2jbnSU0uAgRrFIwTThyhUCqRS+hgZKLS1fJvDm87SNjZGcnsYUAjcQ8vsJ9/Xh7u1FDgRQN20iks3iDA+zZFmYhQLqzZtsj8WY3L0baY2Sf55ICCKpFHUzM2SEQAJCHg+hY8fQDh5EDgRWDoRC1J88SePRo2geD0XAcBy8b98Sv3ePYDZbbf2rFQjLIphMsmDbaEBQVQkePox26BCSz7e6i4bDrDt+nGYhmBscpFAskheC4Js3bPR4qHphFYEnlcI7P4/jdqNpGu8TCe4oCsXr1z//F2ga3+/cSfTJE0qmSVYIsKzaOZDcbjKyzFIiwfvt21kMBLA07YsetzWNd+3tLLW0sH5igvT8PH9Go/z44kX+E4LGjg7GDYOcy4XlOEgLC//5P/5LCFzxOPLmzWyIx+m6fduu7v0NVGqyTSycKksAAAAASUVORK5CYII=)}
		.unchecked-box {list-style-image: url(data:image/png;base64,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)}
		.migrated-box {list-style-image: url(data:image/png;base64,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)}
		ul {list-style-image: none}
		/* ul rule needed to reset style for sub-bullets */
	</style>
</head>
<body>

<!-- Header -->
<div class='header'>
	[ <a href='./Pharmacognosy.html'>Prev</a> ]

	[ <span class='insen'>Index</span> ]

	[ <a href='..\8.html'>Next</a> ]
</div>

<hr />

<!-- Wiki content -->

<div class='pages'>
	<div class='heading'>
	<h1>Pharmacology <a name='7:Pharmacology'></a></h1>
	</div>

	<div class='content'>
	
<p>
 7.  Beta-lactame antibiotics, peptide antibiotics 
</p>

<h1>Beta-lactame antibiotics:</h1>

<p>
<img src="./Pharmacology/pasted_image.png"><br>
<img src="./Pharmacology/pasted_image001.png">
</p>

<p>
OVERVIEW:<br>
→ interfere with the synthesis of bacterial wall<br>
→ they have no effect on bacteria thar are not growning and dividing<br>
→ named after the β-lactam ring that is essential to their activity
</p>

<h2>PENICILLINS:</h2>

<br>

<p>
→ widely effective and less toxic but ↑ resistance<br>
→ differ from an to another in the R substituent attached to 6-aminopenicillianic acid<br>
→ the nature of side chain affect:<br>
<ul>
<li>antimicrobial spectrum</li>
<li>stability to stomach acid</li>
<li>corss-hypersensitiviy </li>
<li>susceptibility to bacterial degradative enzymes(β-lactamase)</li>
</ul>
</p>

<h3>A.Mechanism of Action:</h3>

<p>
→ last step of bacterial wall synthesis (transpeptidation or cross-linkage) → osmotically less stable membrance<br>
<ul>
<li>osmotic pressure</li>
<li>autolysins</li>
</ul>
→ bacteriocidical<br>
→ sucess due to — antibiotic size,charge and hydrophobicity
</p>

<p>
<b>1.Penicillin-binding proteins:(PBPs)</b><br>
→ bacterial enzymes involved in the synthesis (maintain of morphology)<br>
→ mediate peptidoglycan biosynthesis<br>
→ catalyze final transpeptidase reaction 
</p>

<p>
<b>2.Inhibition of transpeptidase</b><br>
→ catalyze formation of the corss-linkage between peptidoglycan chains<br>
→ Penicillins inhibit this transpeptidase-catalyzed reaction
</p>

<p>
<b>3.Production of autolysisn:</b><br>
→ G+ cooci → produce degradative enzymes (autolysins) → normal remodelin of bacterial cell wall<br>
→ when inhibited procced in the absence of cell wall synthesis<br>
→ thus inhibition of cell wall synthesis+ destruction of existing cell wall by autolysins..
</p>

<h3>B.Antibacterial spectrum:</h3>

<p>
→ determined by their ability to cross the bacterial peptidoglycan cell wall to reach PBPs<br>
→ G+ easily traversed by penicillins<br>
→ G- have plus a lipopolysaccharide membrane(envelope) → barrier to water soluble penicillins<br>
→ also has porins to permit the transmembrane entry
</p>

<p>
<b>1.Natural Penicillins</b><br>
→ antistaphylococcal → obtained by the fermentation of the mold <i>Penicillum chyrsogenum</i><br>
→ <i>Ampicillin </i>called semi-synthetic because it differs in the R groups attached to 6-aminopenicillanic acid nuclus<br>
→ <i>Penicillin G(benzylpenicillin) → number of gram-positive and gram-negative cocci, gram-positive bacilli, and spirochete</i><br>
→  Penicillins are susceptible to inactivation by β-lactamases (penicillinases<br>
→ Penicillin V → same spectrum as PG<br>
<ul>
<li>poor absorption</li>
<li>more acidic stable from PG and often employed orally</li>
<li><img src="./Pharmacology/pasted_image003.png"></li>
</ul>
</p>

<p>
<b>2.Antistaphylococcal penicillins</b><br>
→ <i>Methicilin / Nafcillin / Oxacillin / Dicloxacillin</i><br>
<ul>
<li>penicilliase-resistance penicillins </li>
<li>infections produced by penicillase producing bacteria (S.Aureus)</li>
<li>no activity against G-</li>
</ul>
</p>

<p>
<b>3.Extended-spectrum penicillins:</b><br>
→ <i>Ampicillin / Amoxicillin </i><br>
<ul>
<li>spectrum similar to Pen G but ↑ effective against G-</li>
</ul>
→ Ampicillin is drug of choise for the G+ bacilus (<i>Listeria monocytogenes and susceptible Enterococcal species)</i><br>
→ widely used for repsipratory infenctions<br>
<ul>
<li>resistance to these antibiotics is a major clinical problem(inactivation of plasmid-mediated pencillinases)</li>
<li>[Escheria coli and Haemophilus influenzae are frequently resistant]</li>
</ul>
→ formulation with b-lactamase inhibitor such as <i>clavulanic acid+sulbactam </i>protects amoxicillin or ampicillin from enzymatic hydrolysis and extends<br>
their antimicrobial spectrum.<br>
<img src="./Pharmacology/pasted_image005.png">
</p>

<p>
<b>4.Antipseudomonal penicillin:</b><br>
→ <i>Carbenicillin / Ticarcillin and </i> Piperacillin//<br>
<ul>
<li>are called antipseudomonal penicillins because their activity against <i>Pseudomonas aeruginosa</i></li>
</ul>
→ Piperacillin is the most potent<br>
→ effective against many G- bacili<br>
→ Titracillin or piperacililn with clavulanic acid or tazobactam extends spectrum to inlucde penicillase-producing organisms<br>
<img src="./Pharmacology/pasted_image002.png"><br>
<b>5.Penicillins and aminoglycosides</b><br>
→ b-lactam antibiotics synergistic with aminolgycosides<br>
→ can faciliate the entry of other antibiotics  that might not ordinarily gain access to intracellurlar target sites.<br>
→ enchanced antibicrobial activity<br>
[never placed in the same fluid because they prolong contact → + charged aminoglycosides form inactive complex with - charged penicillins]
</p>

<h3>C.RESISTANCE</h3>

<p>
→ natural resistance to penicillins occurs in organism that either <br>
<ul>
<li>lack peptidoglycan cell wall (mycoplasma)</li>
<li>impermable cell walls to the drugs</li>
</ul>
→ can become resistance to multiple agents<br>
<ul>
<li>due to asquisition of a plasmid that encodes resistance to multiple agents → ↑ disemination of the reistance genes</li>
</ul>
</p>

<p>
<b>1.β-lactamase activity:</b><br>
→ enzymes hydrolyzes the cyclic amide bond of b-lactam ring → loss of bactericidal activity<br>
<ul>
<li>major cause of resistance</li>
</ul>
→ b-lactamases are either constitutive or more often asquired by the tranfer of plasmids.<br>
<ul>
<li>some b-lactams are poor substrates → resist hydrolysis</li>
</ul>
</p>

<p>
[certain organims may have chromosome-associated b-lactamases that are inducible b-lactam antibiots[2nd and 3rd cephalosporits]
</p>

<p>
→ G+ secrete β-lactamases extracellulary<br>
→ G- on periplasmatic space between the inner and outer membranes
</p>

<p>
<b>2.Decreased permability to the drug</b><br>
→ ↓ penetration of the antibiotic though the outer cell membrane of bacteria prevents the drug from reaching the PBPs<br>
→ presence of efflux pump can also reducce the drug intracellulary (cytoplasmic and periplasmic protein components which transport the b-lactam antibiotic acrros the outer membrane)
</p>

<p>
<b>3.Alerted PBPs</b><br>
→ modified PBPs have lower affinity of b-lactam antibiotics required clinically unattainable concentrations of the drug in order to be effective against bacterial growth<br>
→ e.g. methicillin resistance in staphylococci and penicillin resistance to pneumonococci and enterococci
</p>

<h3>Pharmacokinetics</h3>

<br>

<p>
<b>1.Administration</b><br>
→ determined by the stability of the drug to gastric acid and by the severity of the infeciton.
</p>

<p>
<b>a.Routes of Admn.</b><br>
→ T<i>icarcillin, piperacillin </i>and the combinations → must be administered intravenously (IV) or intramuscularly (IM)
</p>

<p>
→ P<i>enicillin V, amoxicillin,</i> and <i>amoxicillin</i> combined with <i>clavulanic acid</i> → available only as oral preparations
</p>

<p>
<ul>
<li>Others are effective by the oral, IV, or IM routes (31.6 figure above)</li>
</ul>
</p>

<p>
<b>b.Depot forms</b>
</p>

<p>
→ <i>Procaine penicillin G</i> and <i>benzathine penicillin G</i> are administered IM and serve as depot forms<br>
<ul>
<li>slowly absorbed into the circulation →  persist at low levels over a long time period.</li>
</ul>
</p>

<p>
<b>2.Absorption:</b><br>
→ most Pen are incompletely absorbed after oral amdmn. → reach intestine in sufficient amounts to affect the composition of intestine flora.<br>
<ul>
<li>not appropriate for treatment of Shigella or Salmonella </li>
</ul>
→ All the penicillase resitant penicillins is ↓ absorption by food in the stomach<br>
<ul>
<li>because gastric acid emptying lenghting and the drugs are destroyed in the acidic enviroment of the stomach)</li>
<li>30 to 60 min before meal</li>
</ul>
→ other penicillins are less affected by the food
</p>

<p>
<b>3.Distribution</b><br>
→ distribute well throughout the body<br>
→ all penicillins corss placental barrier but noone has shown teratogenicity<br>
→ bone marrow and CFS penetration is insufficient if the site is not inflammed<br>
<ul>
<li>inflammed meninges are more permable to penicillin,permiting rapid penetration to the CNS,as infection abates,subsites and permability barrieres re-estabilished]</li>
</ul>
→ Penicillin levels in prostate are insufficient to be effective against infenction
</p>

<p>
<b>4.Metabolism</b><br>
→ usually insignificant but some Pen G shown to occur in patient with renal impairment (dosage regiemns adjusted)
</p>

<p>
<b>5.Excretion:</b><br>
→ primary route through the organic acid (tubular) secretory system of the kindeys &amp; glomular filtration<br>
→ half-life of Pen G can ↑ with renal  dysfunction<br>
→ <i>Probenecid </i>inhibit the secration of penicillin by competing the tubular secretion via the organic acid transporter → ↑ blood levels<br>
→ <i>Nafcillin,dicloxiacillin and Oxacillin</i> are exception to the rule and are not eliminated by the kidneys<br>
→ excreted into breast milk
</p>

<h3>E.Adversed reactions</h3>

<p>
<b>1.Hypersensitivity</b><br>
→ most important adverse effect<br>
 → majro antigenic determinant of pen hypersensitivity  is it's metabolite penicillioc acid → reacts with proteins and serves as a hapten to cause immune reaction<br>
<ul>
<li>maculopapular rash (Ampicillin)</li>
<li>angiodema (swelling of lips,tongue...)</li>
<li>anaphylaxis</li>
</ul>
→ Cross allergic reaction <br>
→ safety determination noted by patient severity history <br>
<b>2.Diarhhea</b><br>
→ disruption of the normal balance of intenstinal microorganisms<br>
<ul>
<li>occurs greatly with agents which have incomplete absorption or extended-spectrum</li>
</ul>
<b>3.Nephritis</b><br>
→ particulary Methicillin have the potential [no longer available]<br>
<b>4.Neuphrotoxicity</b><br>
→ irritating neuronal tissue → seizures if injected intrathecally  or ↑ lvl blood<br>
<ul>
<li>epileptic patients are on risk</li>
</ul>
<b>5.Hematologic toxicities</b><br>
→ ↓ coagulation with high dosage of <i>Piperacillin ,Titracillin and Nafcillin </i><br>
<ul>
<li>concern patients with predisposed to uremics or anticoagulants</li>
<li>→ cytopenias occur often after 2 weeks of therapy</li>
</ul>
<b>6.Cation toxicity</b><br>
→ admin. as salts (sodium/sulphate forms)<br>
<ul>
<li>e.g. sodium excess → hypokalemia </li>
</ul>
→ <i>Aqueus Penicillin/Ticarcillin </i> has high sodium load 
</p>

<h2>CEPHALOSPROINS</h2>

<p>
OVERVIEW:<br>
→ β-lactam antibiotics <br>
<ul>
<li>closely related  <i> structually </i> functionally <i> mode of action to penicillins </i> resistance mechanims</li>
</ul>
→ produced semi-synthetically<br>
<ul>
<li>by t he attachment of side chains to 7-aminocephalosporanic acid</li>
</ul>
→ however have greater resistance than Penicillins to certain β-
</p>

<h3>A.ANTI-BACTERIAL SPECTRUM</h3>

<p>
→ clasisfied into 3 generations<br>
<ul>
<li>based on their bacterial susceptibility patterns and resistance to b-lactamase</li>
</ul>
→ comemrcially available cephalosprorins are ineffective against — MRSA,L — monocytogenes — Clostridium difficile — Enterococci<br>
<b>1. 1st Generation:</b><br>
→ act as penicilins G subtitues<br>
→ resistant to <br>
<ul>
<li>Staphylococcal penicillinase and effective against — Proteus mirabilis — E.coli — Klebsiella pneumoniae</li>
</ul>
<b>2nd Generation:</b><br>
→greater activity against three additional G-<br>
<ul>
<li>H.influenzae — Enterobacter aerogenes and some — Neissera species</li>
</ul>
→ <i>Cefotetan and Cefotoxin </i>are effective against anaerobe Bacteroides fragilis (but not prefered because they increase resitance to it)<br>
<b>3. 3rd Generation:</b><br>
→ important role to infectious diseases<br>
→ enchanced activity against G- bacilis(mentioned above) + other enteric organisms — Serratia,marcescens<br>
→ <i>Ceftazidime </i>has activity against P.aeruginosa<br>
→ <i>Ceftriaxone and Cefotaxime </i>has become drug of choise in the treament of meningitis<br>
→ must be used with caution as they are associated with "collateral damage (induction &amp; spread of antimicrobial resistance)<br>
<b>4. 4th Generation </b><br>
→ admin. parentally <br>
→ <i>Cefepime </i>has a wide antibacterial spectrum against — streptococci — Enterobacterial species — E.coli — K.pneumonieae — P.mirabilis — P.aeruginosa<br>
<img src="./Pharmacology/pasted_image006.png">
</p>

<h3>B.RESISTANCE</h3>

<p>
→ Essentially same with penicillin<br>
→ are not susceotible to hydrolysis by the staphylococcal penicillase.<br>
<ul>
<li>might be susceptible to extended spectrum b-lactamases(ESBLs)</li>
<li>E.coli and K.pneumoniae are particurly assosciated with ESBLs</li>
</ul>
</p>

<h3>C. PHARMACOKINETICS</h3>

<p>
<ol type="A" start="4">
<li><img src="./Pharmacology/pasted_image007.png"></li>
</ol>
</p>

<p>
<b>1.Administration </b><br>
→ IV or IM becuase their poor oral absorption
</p>

<p>
<b>2.Distribution</b><br>
→ distribute very well into body fluids<br>
→ <i>Ceftriaxone or Cefotaxime </i> is effective at treatment of <br>
<ul>
<li>neonatal and childhood meningitis caused by H.influenzae</li>
</ul>
→ <i>Cefazolin </i>find application in <br>
<ul>
<li>single prophylaxis dose prior to surgery  (1.8 hrs half life) (orhtopedic surg beucase of the ability to penatrate bone)</li>
</ul>
→ All cephalosporins corss the placenta
</p>

<p>
<b>3.Elimination </b><br>
→ biotransformation by the host in not clinically important<br>
→ tubular secretion and/or glomerual filtration <br>
→ in cases of severe renal failure dosage might be adjusted  ( to guard against accumulation and toxicity)<br>
→ EXCEPTION → <i>Cetriaxone </i>excreted though the bile and feces
</p>

<h3>D.ADVERSE EFFECTS</h3>

<p>
<b>1.Allergic manifestation:</b><br>
→ patients with anaphylactic response <i> Stevens-Johnson syndrome </i> toxic epidermal necrolysis by penicillin SHOUD NOT recieve Cephalosporins<br>
→ crossa activity between Pen and Cepha determined by the similarity on side chan and not on the lactam ring of the structure.<br>
→ highest allergic rate between penicillin and first generation of cephalosporins
</p>

<h1>IV. OTHER BETA LACTAM ANTIBIOTICS</h1>

<br>

<h2>A.CARPAPENEMS</h2>

<p>
→ sythetic b-lactam antibiotics<br>
<ul>
<li>differ in structure from penicillins → sulfur atom of the thiazolidine atom has been extranalized and replaced by a carbon atom</li>
</ul>
→ <i>Imipenpem — Meropenem — doripenem — Ertapenem </i><br>
<ul>
<li>group of drugs currently available </li>
<li>Imipenem is compounded with Cilastatin to protect it from metabolism by renal dehydrogenase</li>
</ul>
</p>

<p>
<b>1,Antibacterial spectrum</b><br>
→ Imipenem reist hydrolysis by most of b-lactamases but not the metallo-b-lactamas<br>
<ul>
<li>against G+/G- organimss — anaerobes — P.aeruginosa</li>
</ul>
→ Meropenem and Doripenem →<br>
<ul>
<li>antibacterial activity similar to Imipenem</li>
</ul>
→ Ertapenem <br>
<ul>
<li>lacks coverage versus Enterococcus species and Acinetobacter species</li>
</ul>
 *<img src="./Pharmacology/pasted_image008.png">
</p>

<h3>Pharmacokinetics</h3>

<p>
→ <i>Imipenem/clistatin and Meropenem </i> are admin. IV and penatrate well into tissues/fluids/CFS<br>
→ excreted by glomerural filtration <br>
<ul>
<li><i>Imipenem </i>undergoues clevage by dehydropeptidase found in proximal renal tube which forms inactive metabolites that is potential nephrotoxic</li>
<li><i>Imipenem/clistatin</i> protects the parent drug by preventing the formation of metabolites</li>
</ul>
→ <i>Meropenem,Ertapenem,Dorpenem</i> do not require co-admn.<br>
<ul>
<li>Ertapenem IV or IM  once a day.</li>
</ul>
</p>

<h3>Adverse effects</h3>

<p>
→ Imipenem/Clistatin can cause nause/vomiting/diarrhea<br>
<ul>
<li>high levels may provoke seizures(Meropenem less likekly to do so)</li>
</ul>
</p>

<br>

<h2>MONOBACTAMS</h2>

<p>
→ disrupt bacterial wall synthesis <br>
<ul>
<li>beta lactam ring does not fused with any other ring</li>
</ul>
→ <i>Azteronam</i><br>
<ul>
<li>antimicrobial activity  against — Enterobacteriaceae (including P.aeruginosa)</li>
<li>lacks activity against G+ and anaerobs</li>
</ul>
→  resistance to b-lactamases with exception of extended spectrum lactamases<br>
→ IV/IM admn<br>
→ can accumulate in patients with renal failure<br>
→ relativity non toxic but can cause<br>
<ul>
<li>phlebitis,skin rash,</li>
</ul>
→ slow immunogenic potential → little cross-activity with antibodies induced by b-lacams → safe alternative to treat patient with allergic history or unable to tolerate penicillin and/or cephalosporins
</p>

<h1>V. β-LACTAMASE INHIBITORS</h1>

<p>
→ hydrolysis of the β-lactam ring either by enzymatic cleavage or by an acid → destroys antimicrobial acitvity of the b-lactam antibiotics<br>
→ β-lactamase inhibitors such as <br>
<ul>
<li><i>Clavulanic acid </i> Sulbactam <i> Tazobactam →</i>contain a β-lactam ring but themselfs does not have an antibacterial activity </li>
</ul>
→ they bind to  and inactivate b-lactamases,therby protecting the antibiotics that are normaly substrates of these enzymes<br>
→ b-lactamases inhibitors formulated on combination with β-lactamase sensitive antibiotics<br>
<ul>
<li><i>clavulanic acid and amoxicillin </i> on the growth of β-lactamase producing E.coli</li>
</ul>
</p>

<h2>VANCOMYCIN</h2>

<p>
→ tricylic glycopeptide <br>
→ effective against multiple drug-resistant organisms — MRSA — Enterococci <br>
→ <i>Bacitarcin </i> is a mixture of polypeptides that also inhibts bacterial cell wall synthesis<br>
[topical application usage because of its potential to nephrotoxicity with systemic use]
</p>

<h3>A.Mechanms of action</h3>

<p>
→ Vancomycin inhibits<br>
<ul>
<li>becterial cell wall phospholipids + peptidoglycan polymerization in a time-dependant fashion</li>
<li>by binding to D-Ala-D-Ala side chain of the prescusor pentapeptide</li>
</ul>
→ prevents the transglycosylation of peptidoglycan polymeraziation → weakening the cell wall damaging the underlying cell membrane.
</p>

<h3>B.Antibacterial spectrum</h3>

<p>
→ against G+<br>
→ treatment of MRSA and methicillin-resistance — Staphylococcus epidermidis + Enterococcical infenctions<br>
→ vancomycin resistant bacteria — Enterococci faecium/faecalis<br>
→ Oral vancomycin limited on the treatment of life-threating colitis<br>
→ Intravenous vancomysin used in individuals with prosthetic heart valves<br>
→ Vancomycin acts synergastically with aminoglycosides → in treatment of enterococcal endocarditis.<br>
→ <i>Daptomycin → </i>cylcic lipopeptide antibiotic + two protein synthesis inhibitors <i>Quinopristin/Daflopristin/Linezolid</i><br>
<ul>
<li>are currently available for the treatment of vanocmysin-resistant organisms.</li>
</ul>
<img src="./Pharmacology/pasted_image009.png">
</p>

<h3>C.RESISTANCE</h3>

<p>
→ can be caused by plasmid-mediated changes in permabilty to the drug or<br>
→ by ↓ binding to receptor molecules [e.g. replacement of a D-Ala by D-lactate in resistant organism]
</p>

<h3>D.PHARMACOKINETICS</h3>

<p>
→ slow IV-infusions (60-90min) of vancomycin is employed for treatment of systemic infenctions or prophylaxis<br>
→ not absorbed orally <br>
→ inflammation allows the intravenous formulation to penatrate into the meningitis(synergistic effect with <i>Ceftriaxone)</i><br>
→ metabolism is minimal to 90-100% excreted by glomerular filtration.<br>
<ul>
<li>doasage must be adjusted for patien with renal dysfunction</li>
<li>normal half life is 6-10hrs compared to over 200hrs in end-stage renal disease.</li>
</ul>
</p>

<h3>E.ADVERSE EFFECTS</h3>

<p>
→ fever,chills and/or phlebitis at the infusion site<br>
→ flushing("red man syndrome") + shock result from histamine release associated with rapid infusion<br>
→ dose-related hearing loss hs occured in patients with renal failur who accumulate the drug<br>
→ Ototoxicity and nephrotoxicity are common when vancomycin is administrated in combination with aminoglycosides
</p>

<h1>VII.DAPTOMYCIN</h1>

<p>
→ cyclic lipopetide antibiotic which is alternative to other agents such as <i>Linezolid,Quinupristin/Daflopristin</i><br>
<ul>
<li>for treating infenctions caused by resistant G+</li>
</ul>
</p>

<h3>a.Mechanism of action</h3>

<p>
→ upond binding to bacterial cytoplasmatic membrane → induce a rapid depolaraziation of the membrane → disrupting multiple aspects of membrane function <br>
&amp; inhibiting intracellular synthesis of DNA,RNA and   protein.<br>
→ bactericidal (concentration dependent)
</p>

<h3>b.Antibacterial spectrum</h3>

<p>
→ limited to G+ which includes — MSSA,MRSA,penicillin-resistant Streptococcus pneumoniae,pyogens,Corynebacterium jeikeium,E.facialies,faecium<br>
→ indicated for complicated skin and skin struture infencitons<br>
→ inactivitaed by pulmonary surfactants → NEVER be used in the treatment of pneumonia.
</p>

<h3>c.Pharmacokinetics</h3>

<p>
→ 90-95% protein bound<br>
→ does not appear to goes hepatic metabolism
</p>

<h3>d.Adverse effects</h3>

<p>
→ constipation,nausea,headache,myalgias and isomnia<br>
→ ↑ hepatic transaminases and ↑ in creatine phosphokinases
</p>

<h1>VIII.TELAVACIN</h1>

<p>
→ semi-synthetic lipoglycopeptide antibiotic that is a synthetic derivative of Vancomycin<br>
→ alternative to vancomycin,daptomycin,linezolid,quinupristin,daflopristin<br>
→ skin infenctions by G+(including MRSA)
</p>

<h3>a.Mechanism of action</h3>

<p>
→ inhibit bacterial cell wall synthesis(like vancomycin) but exhibits an additional mechanism of action similar of that of daptomycin(unlike vancomysin)<br>
→ disruption of the bacterial cell membrane due to the presence of the lipophilic side chain moeity
</p>

<h3>b.Antibacterial Spectrum</h3>

<p>
→ bacteriocidical against — Staphylococcus aureus, — Streptococcus agalctiae — Penicillin reisistant Streptococcus pneumoniae — vancomycin-suscpetible Enterococcus faecalis isolates.
</p>

<h3>c.Pharmacokinetics</h3>

<p>
→ half life 7-9hrs<br>
→ it's uncertain if undergoes hepatic metabolism<br>
→ admn. 10mg/kg via 60min infusion every 24hrs<br>
→ with patients with creatine clearence 7.5mg/kg/day
</p>

<h3>d.Adverse effects</h3>

<p>
→ taste disturbances,nause,vommiting,insomnia,foamy urine<br>
→ not recommended during pregnancy<br>
→ may prolong QT interval (avoided heart failure,severe left ventricular hypertrohphy)<br>
→ monitor coagulation<br>
<img src="./Pharmacology/pasted_image010.png"><br>
<img src="./Pharmacology/pasted_image011.png">
</p>


	</div>

	<br />

	<div class='page-footer'>

			<b>Attachments:</b>
			<table>

			<tr><td><a href='./Pharmacology/pasted_image.png'>pasted_image.png</a></td><td>&nbsp;</td><td>99.8kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image001.png'>pasted_image001.png</a></td><td>&nbsp;</td><td>31.0kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image002.png'>pasted_image002.png</a></td><td>&nbsp;</td><td>74.9kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image003.png'>pasted_image003.png</a></td><td>&nbsp;</td><td>122kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image004.png'>pasted_image004.png</a></td><td>&nbsp;</td><td>122kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image005.png'>pasted_image005.png</a></td><td>&nbsp;</td><td>54.2kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image006.png'>pasted_image006.png</a></td><td>&nbsp;</td><td>85.2kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image007.png'>pasted_image007.png</a></td><td>&nbsp;</td><td>154kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image008.png'>pasted_image008.png</a></td><td>&nbsp;</td><td>109kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image009.png'>pasted_image009.png</a></td><td>&nbsp;</td><td>56.3kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image010.png'>pasted_image010.png</a></td><td>&nbsp;</td><td>94.7kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image011.png'>pasted_image011.png</a></td><td>&nbsp;</td><td>390kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image012.png'>pasted_image012.png</a></td><td>&nbsp;</td><td>333kb</td></tr>

			</table>
	</div>

	

</div>

</body>
</html>
